Akoya Biosciences, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Akoya Biosciences, Inc. has completed its merger with Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix Corporation, resulting in Akoya becoming a wholly-owned subsidiary of Quanterix.
Akoya Biosciences, Inc. stockholders overwhelmingly approved the proposed merger with Quanterix Corporation at a special meeting held on July 7, 2025.
Akoya Biosciences announced that Party A has withdrawn its unsolicited all-cash acquisition proposal, with Akoya's board reaffirming its commitment to the previously announced merger with Quanterix Corporation.
Akoya Biosciences received an unsolicited all-cash acquisition proposal of $1.40 per share from a third party while already in a merger agreement with Quanterix.
Akoya Biosciences announced its Q1 2025 financial results, highlighting revenue of $16.6 million and progress in spatial biology adoption, while also noting a pending acquisition by Quanterix Corporation.
Quanterix and Akoya Biosciences have amended their merger agreement, reducing the number of Quanterix shares to be issued and adding a cash component for Akoya shareholders.
Akoya Biosciences enters into a securities purchase agreement with Quanterix for up to $30 million in convertible notes, contingent on the ongoing merger agreement.
8-K: Akoya Biosciences Reports Q4 and Full Year 2024 Financial Results; Acquisition by Quanterix Pending
Akoya Biosciences announced its Q4 and full year 2024 financial results, highlighting revenue decline, gross margin improvement, operating expense reduction, and a pending acquisition by Quanterix Corporation.
Akoya Biosciences and Quanterix move closer to merging as the Hart-Scott-Rodino Act waiting period expires, with the deal expected to close in the second quarter of 2025.
8-K: Quanterix to Acquire Akoya Biosciences in All-Stock Deal, Creating Integrated Biomarker Solution
Quanterix will acquire Akoya Biosciences in an all-stock transaction, creating the first integrated solution for ultra-sensitive detection of bloodand tissue-based protein biomarkers.
Akoya Biosciences has updated its indemnification agreement for non-employee directors and executive officers, providing expanded coverage and protections.
Akoya Biosciences announced third quarter 2024 financial results that fell below expectations due to capital equipment purchase constraints in the life science tools market.
Akoya Biosciences has appointed Scott Mendel as Chairman of the Board, effective immediately, succeeding Robert Shepler who remains a board member.
Akoya Biosciences announced a 26% sequential revenue increase in Q2 2024, alongside significant reductions in operating expenses and a narrowed loss from operations.
Akoya Biosciences held its 2024 Annual Meeting of Stockholders on June 4, 2024, where stockholders voted on the election of three Class III Directors and the ratification of the company's independent auditor.
Akoya Biosciences' first quarter 2024 revenue decreased by 14% year-over-year to $18.4 million, though reagents and services revenue saw continued growth.
Akoya Biosciences announced record fourth-quarter revenue of $26.5 million and provided a full-year 2024 revenue guidance of $114.0-118.0 million, with a target of operating cash flow breakeven by the end of 2024.